Hypereosinophilic syndrome-a rare adverse event of anti-cytokine treatment in rheumatoid arthritis resolved after Janus kinase inhibitor therapy.
Anti-cytokine therapy
Baricitinib
Eosinophilia
Rheumatoid arthritis
Vasculitis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
07
03
2020
accepted:
23
04
2020
revised:
19
04
2020
pubmed:
5
6
2020
medline:
15
5
2021
entrez:
5
6
2020
Statut:
ppublish
Résumé
Eosinophilia is uncommon in early rheumatoid arthritis (RA). The most frequent causes of hypereosinophilia during RA treatment are atopic eczema, allergy, helminth infection, haematological malignancy and drug-associated complications. The pathogenesis of this abnormality associated with anti-cytokine therapy is still unknown. We report the case of a young woman with RA and eosinophilia accompanied by systemic symptoms such as dyspnoea, fluid retention and eosinophilic vasculitis. An interesting observation was the persistence of eosinophilia during treatment with various biologics and its normalization after switching to the Janus kinase inhibitor baricitinib.
Identifiants
pubmed: 32495227
doi: 10.1007/s10067-020-05134-z
pii: 10.1007/s10067-020-05134-z
doi:
Substances chimiques
Cytokines
0
Janus Kinase Inhibitors
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3507-3510Références
Kovalszki A, Weller PF (2016) Eosinophilia. Prim Care 43(4):607–617
doi: 10.1016/j.pop.2016.07.010
Guellec D, Milin M, Cornec D, Tobon GJ, Marhadour T, Jousse-Joulin S, et al (2015) Eosinophilia predicts poor clinical outcomes in recent-onset arthritis: results from the ESPOIR cohort. RMD Open 2015; published on 15 July. https://doi.org/10.1136/rmdopen-2015-000070
Panush RS, Franco AE, Schur PH (1971) Rheumatoid arthritis associated with eosinophilia. Ann Intern Med 75(2):199–205
doi: 10.7326/0003-4819-75-2-199
Rothenberg ME (1998) Eosinophilia. N Engl J Med 338(22):1592–1600
doi: 10.1056/NEJM199805283382206
Savolainen HA, Leirisalo-Repo M (2001) Eosinophilia as a side-effect of methotrexate in patients with chronic arthritis. Clin Rheumatol 20(6):432–434
doi: 10.1007/PL00011213
Edelman J, Davis P, Gwen ET (1983) Prevalence of eosinophilia during gold therapy for rheumatoid arthritis. J Rheumatol 10:121
pubmed: 6405032
Nakahigashi K, Egawa G, Miyachi Y, Kabashima K (2014) Digital vasculitis with eosinophilia possibly associated with etanercept therapy. Acta Derm Venereol 94(2):239–240
doi: 10.2340/00015555-1662
Azuma N, Matsui K, Hashimoto N, Yoshikawa T, Sano H (2017) Successful switch to golimumab for eosinophilia and skin symptoms related to multiple biologics in a patient with rheumatoid arthritis. Intern Med 56(12):1585–1590
doi: 10.2169/internalmedicine.56.8168
Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, Hsia EC, Han J, Wagner C, Xu Z, Visvanathan S, Rahman MU (2008) Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 58(4):964–975
doi: 10.1002/art.23383
Leu JH, Adedokun OJ, Gargano C, Hsia EC, Xu Z, Shankar G (2019) Immunogenicity of golimumab and its clinical relevance in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Rheumatology (Oxford) 58(3):441–446
doi: 10.1093/rheumatology/key309
Jani M, Isaacs JD, Morgan AW, Wilson AG, Plant D, Hyrich KL, Chinoy H, Barton A, BRAGGSS (2017) High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. Ann Rheum Dis 76(1):208–213
doi: 10.1136/annrheumdis-2015-208849
Ogata A, Tanimura K, Sugimoto T, Inoue H, Urata Y, Matsubara T, Kondo M, Ueki Y, Iwahashi M, Tohma S, Ohta S, Saeki Y, Tanaka T, the Musashi Study Investigators (2014) Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken) 66:344–354
doi: 10.1002/acr.22110
Simon HU, Blaser K (1995) Inhibition of programmed eosinophil death: a key pathogenic event for eosinophilia? Immunol Today 16:53–55
doi: 10.1016/0167-5699(95)80086-7
Bystrom J, Clanchy FI, Taher TE (2017) Response to treatment with TNFα inhibitors in rheumatoid arthritis is associated with high levels of GM-CSF and GM-CSF+ T lymphocytes. Clin Rev Allergy Immunol 53(2):265–276
doi: 10.1007/s12016-017-8610-y
Simon HU, Yousefi S, Dibbert B, Levi-Schaffer F, Blaser K (1997) Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via JAK2 tyrosine kinase in eosinophils. Eur J Immunol 27(12):3536–3539
doi: 10.1002/eji.1830271256
Yousefi S, Hoessli DC, Blaser K, Mills GB, Simon HU (1996) Requirement of Lyn and Syk tyrosine kinases for the prevention of apoptosis by cytokines in human eosinophils. J Exp Med 183(4):1407–1414
doi: 10.1084/jem.183.4.1407